Pterostilbene Silbinol (Pterocarpus marsupium)

Pterostilbene Silbinol, derived from Pterocarpus marsupium heartwood, is a naturally occurring stilbenoid structurally similar to resveratrol but with superior bioavailability due to two methoxy groups replacing hydroxyl groups. It exerts antioxidant and neuroprotective effects primarily by modulating NF-κB and PI3K/Akt signaling pathways, reducing oxidative stress and inflammation at the cellular level.

Origin & History

Pterostilbene Silbinol is a branded, standardized extract (Silbinol®) derived from the bark of the Pterocarpus marsupium tree native to India. The extract is standardized to contain >90% pterostilbene, a dimethylated analog of resveratrol with enhanced bioavailability and stability.

Historical & Cultural Context

No historical or traditional medicine context for Pterocarpus marsupium or pterostilbene use was documented in the available research. The compound appears to be primarily studied as a modern nutraceutical ingredient.

Health Benefits

• Demonstrated safety profile in healthy adults with no adverse effects on vital signs or blood parameters (moderate evidence from one RCT, PMID: 37671486)
• Potential antioxidant activity through modulation of NF-κB and PI3K/Akt signaling pathways (preliminary evidence from mechanistic studies)
• May support cognitive function due to blood-brain barrier penetration capabilities (preliminary evidence, no human efficacy trials)
• Possible anti-inflammatory effects based on stilbenoid structure (theoretical based on mechanism, no clinical trials)
• Superior bioavailability compared to resveratrol due to resistance to glucuronidation (preliminary pharmacokinetic evidence)

How It Works

Pterostilbene inhibits NF-κB nuclear translocation, suppressing pro-inflammatory cytokine transcription including TNF-α and IL-6. It also activates the PI3K/Akt survival signaling cascade, which promotes neuronal resilience and reduces apoptotic signaling via modulation of Bcl-2 family proteins. Its dimethylated structure relative to resveratrol confers greater lipophilicity, resulting in estimated oral bioavailability of approximately 80% versus roughly 20% for resveratrol, enabling more efficient cellular penetration and sustained plasma concentrations.

Scientific Research

The primary human evidence comes from a randomized, double-blind, placebo-controlled safety study (n=60 healthy adults) showing Silbinol® at 200 mg/day for 60 days produced no significant changes in hematological, lipid, glycemic, thyroid, liver, or renal profiles (PMID: 37671486). No efficacy trials for therapeutic outcomes were identified, with researchers calling for more human studies to establish clinical benefits.

Clinical Summary

One randomized controlled trial (PMID: 37671486) evaluated Pterostilbene Silbinol in healthy adults and reported no adverse effects on vital signs, complete blood count, or metabolic blood parameters, establishing a preliminary safety foundation. The study sample size was modest, limiting statistical power for efficacy conclusions, and the evidence is therefore rated moderate for safety rather than efficacy. Most mechanistic data supporting antioxidant and anti-inflammatory effects originate from in vitro cell culture and preclinical animal models rather than adequately powered human trials. Larger, placebo-controlled clinical trials measuring cognitive endpoints such as processing speed, working memory, or biomarkers like BDNF are needed before definitive efficacy claims can be substantiated.

Nutritional Profile

Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene) is the primary bioactive stilbenoid compound isolated from Pterocarpus marsupium heartwood. Silbinol® is a standardized extract typically containing 5–10% pterostilbene by weight, alongside minor phenolic constituents including marsupsin, pterosupin, and epicatechin. Key bioactive compounds: • Pterostilbene: a dimethylated analog of resveratrol (molecular weight 256.3 g/mol), present at approximately 50–100 mg per gram of standardized extract; exhibits significantly higher oral bioavailability (~80%) compared to resveratrol (~20%) due to the two methoxy groups enhancing lipophilicity and metabolic stability. • Epicatechin: a flavan-3-ol present in minor quantities (~1–3% of extract), contributing to antioxidant capacity. • Marsupsin and pterosupin: unique bicyclic dihydrochalcones found in Pterocarpus marsupium bark and heartwood, present at trace to low concentrations (~0.5–2%), with reported hypoglycemic activity. • Additional polyphenolic tannins and flavonoids in trace amounts. The extract is not a significant source of macronutrients (protein, fat, carbohydrates, fiber) or essential vitamins/minerals, as it is consumed in milligram-level doses (typical supplemental dose: 50–450 mg/day of extract, delivering approximately 25–250 mg pterostilbene). Bioavailability notes: Pterostilbene has a half-life of approximately 77–105 minutes in humans, undergoes Phase II hepatic metabolism primarily via glucuronidation and sulfation, and demonstrates capacity to cross the blood-brain barrier. Its lipophilic nature (logP ~3.0) facilitates cellular membrane permeability and tissue distribution, particularly to brain, liver, and adipose tissue. Peak plasma concentrations are reached within 1–2 hours post-oral ingestion. Co-administration with food or lipid-based carriers may further enhance absorption, though specific food-effect data in humans remain limited.

Preparation & Dosage

The clinically studied dose of Silbinol® is 200 mg/day (standardized to >90% pterostilbene), taken as 100 mg capsules twice daily with meals, based on the 60-day safety trial. No other dosage forms or therapeutic doses have been clinically evaluated. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Resveratrol, Curcumin, Green Tea Extract, NAD+ precursors, Quercetin

Safety & Interactions

Based on available clinical data (PMID: 37671486), Pterostilbene Silbinol appears well-tolerated in healthy adults at studied doses, with no significant changes in hematological or biochemical markers. Because pterostilbene inhibits certain CYP450 enzymes in preclinical models, theoretical interactions with drugs metabolized by CYP2C9 and CYP2C19—such as warfarin, phenytoin, or certain statins—cannot be ruled out and warrant caution. Pterostilbene's structural similarity to resveratrol raises a theoretical concern regarding additive effects when co-administered with anticoagulants or antiplatelet agents like aspirin or clopidogrel. Safety data in pregnant or lactating women, children, and individuals with hepatic impairment are absent, and use in these populations should be avoided until further research is available.